Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVNAYE)

Drug Name

MK-8521 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Type-2 diabetes	5A11	Phase 2	[1]

Cross-matching ID

TTD Drug ID: DMVNAYE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glucagon (GCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PB-1023	DMZCI04	Type-2 diabetes	5A11	Phase 2	[2]
JNJ-64565111	DMVSUH1	Obesity	5B81	Phase 2	[2]
MEDI0382	DMSV60C	Type-2 diabetes	5A11	Phase 2	[2]
PT320	DMZYKXN	Parkinson disease	8A00.0	Phase 2	[3]
SAR425899	DM53IPE	Diabetic complication	5A2Y	Phase 1	[2]
ZP2929	DMRVDUM	Type-1 diabetes	5A10	Phase 1	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting Glucagon receptor (GCGR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucagon recombinant	DMFLUTR	Hypoglycemia	5A41	Approved	[4]
Dasiglucagon	DM74SVE	Hypoglycemia	5A41	Approved	[5]
Retatrutide	DM8WU0Q	Obesity	5B81	Phase 3	[6]
LY2944876	DML6XWR	Diabetic complication	5A2Y	Phase 2	[7]
TT-401	DMRQ0SA	Type-2 diabetes	5A11	Phase 2	[2]
LGD-6972	DMPL9KG	Type-2 diabetes	5A11	Phase 2	[8]
PF-06291874	DMN94QM	Type-2 diabetes	5A11	Phase 2	[9]
LY-2409021	DMZOIP4	Type-2 diabetes	5A11	Phase 2	[10]
REMD 477	DM13OVF	Type-1 diabetes	5A10	Phase 2	[11]
Efinopegdutide	DMAN2V2	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucagon (GCG)	TT0NUFM	GLUC_HUMAN	Co-agonist	[2]
Glucagon receptor (GCGR)	TT9O6WS	GLR_HUMAN	Co-agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02492763) A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci. 2021 Mar 16;4(2):858-869.
4	Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
6	Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
7	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
9	Clinical pipeline report, company report or official report of pfizer.
10	Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
11	Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.
12	Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.